

Shionogi Announces the Continued Expansion of their Operations in Europe with the Launch of Shionogi Italy

ROME, ITALY. 7th JULY 2015 – Shionogi Europe today announced the continued expansion of their operations in Europe with the launch of their offering in Italy. In 2012, Shionogi & Co., Ltd. launched its European Headquarters in London and is proud to be expanding the global business into Italy this year.

Today, Shionogi’s vision is to continue to grow as a drug discovery based company, capable of independently creating and offering products globally. Dating back from 1878, the company has been involved in research, development, manufacturing and marketing activities for over 130 years and are defined by a distinct openness and close partnership approach to creating medicines.

“We are very proud to continue building our presence in Europe with the launch of our offering in Italy,” said Takashi Takenoshita, CEO of Shionogi Europe. “We are committed to the research and development of innovative drugs in areas of unmet medical need and supplying the best possible medicines to protect the health and wellbeing of the patients we serve. Our aim is to achieve this with a strong presence in Europe, which conducts business operations recognised by patients, their families, healthcare providers and the broader community. In Italy, Shionogi already has over 20 clinical trial centres for infectious diseases and hematology and we are also delighted to be extending the Shionogi Science Programme to Italy this year.”

Shionogi Europe is a research-led organisation, defined by a distinct openness and close partnership approach to creating medicines, with a strong focus on infectious diseases, pain, metabolic disorder, women’s health and immune oncology. Previously Shionogi has licenced to known multinationals in Europe some of its molecules – rosuvastin for the treatment of metabolic diseases and dolutegravir for the treatment of HIV infections.

“In Autumn 2015, in line with Shionogi’s vision to create and offer products globally under the Shionogi name, we will launch our first product here in Italy.” said Simona Falciai, General Manager, Italy. “Ospemifene is a significant innovation for women with vulvar and vaginal atrophy (VVA) and is in response to a key unmet need in the area of menopause.”





About Shionogi Europe

Shionogi Europe is the European Headquarters of Shionogi & Co., Ltd., a Japanese pharmaceutical company with a 137-year history discovering and developing innovative therapies. Shionogi Europe continues this focus on the development and commercialisation of high quality medicines that protect the health and well-being of the patients we serve. Our pipeline is focussed on infectious diseases, pain, metabolic disorder, women's health and immune oncology. For more information, please visit www.shionogi.eu for Shionogi Europe and www.shionogi.co.jp/en for Shionogi & Co., Ltd.

Forward Looking Statement

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.